The article "Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy" describes a case study of a patient with cutaneous squamous cell carcinoma (cSCC) that had recurred multiple times and had developed resistance to previous treatments. The patient had a genomic profile showing mutations in the MEK and PIK3CA genes, which are known to be involved in cancer progression and resistance to therapy. The patient was treated with a combination of trametinib, a MEK inhibitor, and metformin, a drug commonly used to treat diabetes that has shown potential as an anticancer agent.

‍

Key Takeaways:

• The article describes a case study of a patient with cutaneous squamous cell carcinoma (cSCC) that had recurred multiple times and had developed resistance to previous treatments.
• The patient had a genomic profile showing mutations in the MEK and PIK3CA genes, which are known to be involved in cancer progression and resistance to therapy.
• The patient was treated with a combination of trametinib, a MEK inhibitor, and metformin, a drug commonly used to treat diabetes that has shown potential as an anticancer agent.
• The patient achieved a complete clinical response to the treatment, with no evidence of recurrence after more than two years of follow-up.
• This case study suggests that the combination of trametinib and metformin may be an effective treatment option for cSCC patients with MEK mutations and PIK3CA amplifications, and warrants further investigation in clinical trials.

‍

Read the entire article here.

‍Remenár É, Dóczi R, Dirner A, Sipos A, Perjési A, Tihanyi D, Vodicska B, Lakatos D, Horváth K, Kajáry K, Schwáb R, Déri J, Lengyel CG, Várkondi E, Vályi-Nagy I, Peták I.
JCO Precis Oncol. 2022 Jan;6:e2100344. doi: 10.1200/PO.21.00344. PMID: 35005996.

‍